Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms.

Circ Arrhythm Electrophysiol

From the Cardiology Division (C.M.H., P.R.K.) and Lankenau Institute for Medical Research (V.M.R., P.R.K.), Lankenau Medical Center, Wynnewood, PA.

Published: March 2016

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCEP.115.002479DOI Listing

Publication Analysis

Top Keywords

status antiarrhythmic
4
antiarrhythmic drug
4
drug development
4
development atrial
4
atrial fibrillation
4
fibrillation drugs
4
drugs molecular
4
molecular mechanisms
4
status
1
drug
1

Similar Publications

Dynamics and regulatory roles of RNA mA methylation in unbalanced genomes.

Elife

January 2025

Key Laboratory of Cell Proliferation and Regulation Biology of Ministry of Education, College of Life Sciences, Beijing Normal University, Beijing, China.

-methyladenosine (mA) in eukaryotic RNA is an epigenetic modification that is critical for RNA metabolism, gene expression regulation, and the development of organisms. Aberrant expression of mA components appears in a variety of human diseases. RNA mA modification in has proven to be involved in sex determination regulated by and may affect X chromosome expression through the MSL complex.

View Article and Find Full Text PDF

Objectives: We present a case series of patients with granulomatous myocarditis presenting as atrial arrhythmias accompanied by lymphadenopathy.

Background: Atrial myocarditis (AM) may be the cause of atrial fibrillation (AF) in patients without risk factors.

Methods: Patients with atrial fibrillation without risk factors underwent 18F-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET).

View Article and Find Full Text PDF

Background: Ventricular fibrillation (VF) is a vicious arrhythmia usually generated after removal of the aortic cross-clamp (ACC) in patients undergoing open-heart surgery, which could damage cardiomyocytes, especially in patients with left ventricular hypertrophy (LVH). Amiodarone has the prominent properties of converting VF and restoring sinus rhythm. However, few studies concentrated on the effect of amiodarone before ACC release on reducing VF in patients with LVH.

View Article and Find Full Text PDF

Case report of entrectinib associated fulminant myocarditis.

Eur Heart J Case Rep

January 2025

Department of Cardiology, York Hospital, WellSpan Health, 30 Monument Rd, York, PA 17403, USA.

Background: ROS1 tyrosine kinase inhibitors are one of the primary immunotherapies for fusion-positive cancers. Tyrosine kinase inhibitors have markedly improved outcomes for advanced cancers previously with poor prognosis. Entrectinib is an example of an ROS1 inhibitor that can be used for lung adenocarcinoma.

View Article and Find Full Text PDF

Degenerative retinal diseases can lead to blindness if left untreated. At present, there are no curative therapies for retinal diseases. Therefore, effective treatment strategies for slowing the progression of retinal diseases and thus improving patients' life standards are urgently needed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!